GID BIO Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.34M
- Investors
-
3
GID BIO General Information
Description
Developer of cellular therapies technology intended to enable cell-based treatments for osteoarthritis of the knee and other diseases. The company's technology harvests and isolates a patient's stromal and vascular cells, including stromal progenitor cells, to help control pain, reduce inflammation, and repair inflamed tissues, enabling healthcare providers to offer patients a walk-in and walk-out procedure for tissue harvest and cellular implant.
Contact Information
Website
www.gidbio.comCorporate Office
- 901 Front Street
- Suite 240
- Louisville, CO 80027
- United States
Corporate Office
- 901 Front Street
- Suite 240
- Louisville, CO 80027
- United States
GID BIO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 30-Dec-2021 | $5.34M | Completed | Generating Revenue | ||
| 5. Grant | 18-Aug-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 20-Jan-2020 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 10-Jan-2014 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 01-Dec-2011 | $2.66M | $5.16M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 19-May-2010 | $2.5M | $2.5M | Completed | Generating Revenue |
GID BIO Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 325,000 | $0.001000 | $8.9 | $8.9 | 1x | $8.9 | 26.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GID BIO Patents
GID BIO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230332094-A1 | Adipose tisssue processing method | Active | 18-Jul-2017 | ||
| EP-3655518-A1 | Adipose tissue digestion system and tissue processing method | Pending | 18-Jul-2017 | ||
| EP-3655518-A4 | Adipose tissue digestion system and tissue processing method | Pending | 18-Jul-2017 | ||
| US-11732233-B2 | Adipose tissue digestion system and tissue processing method | Active | 18-Jul-2017 | ||
| US-20200181561-A1 | Adipose tissue digestion system and tissue processing method | Active | 18-Jul-2017 | C12M45/09 |
GID BIO Signals
GID BIO Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Richard King Mellon Foundation | Limited Partner | |||
| Ithaka Partners | Growth/Expansion | Minority | ||
| Eagles Ketch | Asset Manager | Minority |
GID BIO FAQs
-
When was GID BIO founded?
GID BIO was founded in 2008.
-
Where is GID BIO headquartered?
GID BIO is headquartered in Louisville, CO.
-
What is the size of GID BIO?
GID BIO has 8 total employees.
-
What industry is GID BIO in?
GID BIO’s primary industry is Drug Discovery.
-
Is GID BIO a private or public company?
GID BIO is a Private company.
-
What is GID BIO’s current revenue?
The current revenue for GID BIO is .
-
How much funding has GID BIO raised over time?
GID BIO has raised $35.2M.
-
Who are GID BIO’s investors?
Richard King Mellon Foundation, Ithaka Partners, and Eagles Ketch have invested in GID BIO.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process